Supplementary Table 3. AE ≥ grade 3 and hospitalisation considering PPI >50.
| Cohort 1: Capecitabinea | Cohort 2: 5-FU | |||||||
|---|---|---|---|---|---|---|---|---|
| Overall (243) | PPI >50 (31) | Non-PPI (212) | p value | Overall (196) | PPI >50 (27) | Non-PPI (169) | p value | |
| All | 39.5% | 35.5% | 40.1% | 0.70 | 29.1% | 40.7% | 27.2% | 0.17 |
| Diarrhoea | 21.4% | 22.6% | 21.2% | 0.89 | 12.8% | 18.5% | 11.8% | 0.33 |
| HFS | 16.0% | 9.7% | 17.0% | 0.30 | 0 | 0 | 0 | - |
| Infection | 2.9% | 3.2% | 2.8% | 1.00 | 4.6% | 0 | 5.3% | 0.22 |
| Rectitis | 6.6% | 9.7% | 6.1% | 0.46 | 8.7% | 11.1% | 8.3% | 0.63 |
| Cystitis | 18.1% | 3.2% | 20.3% | 0.02 | 0.5% | 0 | 0.6% | 0.69 |
| Oral mucositis | 6.2% | 3.2% | 6.6% | 0.46 | 9.7% | 11.5% | 9.0% | 0.69 |
| Other | 2.5% | 3.2% | 2.4% | 0.77 | 5.6% | 11.1% | 4.7% | 0.18 |
| Hospitalisation | 6.1% | 3.2% | 6.5% | 0.47 | 9.2% | 11.1% | 8.9% | 0.71 |
| ICU | 1.2% | 3.1% | 0.9% | 0.28 | 1.5% | 3.7% | 1.2% | 0.32 |
a
Missing data of 8 of 251 patients
PPI>50: use of proton-pump inhibitors for at least 50% of the neoadjuvant period; PPI: proton-pump inhibitors; HFS: hand and foot syndrome; ICU: Intensive care unit
The bold values represent statistical significant differences in the occurrence of AE>= grade 3 and hospitalization between PPI>50 and non-PPI>50 groups